Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Colorcon
UBS
QuintilesIMS
Accenture
Daiichi Sankyo
Teva
Medtronic
Fuji
AstraZeneca

Generated: January 17, 2018

DrugPatentWatch Database Preview

Crofelemer - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for crofelemer and what is the scope of crofelemer freedom to operate?

Crofelemer
is the generic ingredient in one branded drug marketed by Napo Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Crofelemer has thirty-eight patent family members in twenty-one countries.

One supplier is listed for this compound.
Summary for crofelemer
International Patents:38
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 9
Drug Prices:see low prices
DailyMed Link:crofelemer at DailyMed
Pharmacology for crofelemer
Drug ClassAntidiarrheal

US Patents and Regulatory Information for crofelemer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for crofelemer

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
McKinsey
Johnson and Johnson
Merck
Accenture
Healthtrust
Fuji
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot